Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial

2019106 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet. Gastroenterology & hepatology

Volume 5, Issue 2, pp. 152-166

Field-Weighted Citation Impact: 11.16